S. X. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. K. Hei, Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011.

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. et al., Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

D. Jean and M. C. Jaurand, Causes and pathophysiology of malignant pleural mesothelioma, Lung Cancer Management, vol.4, p.10, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02483449

G. Guo, J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev et al., Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma, Cancer Res, vol.75, pp.264-273, 2015.

A. De-rienzo, M. A. Archer, B. Y. Yeap, N. Dao, D. Sciaranghella et al., Gender-Specific Molecular and Clinical Features underlie Malignant Pleural Mesothelioma, Cancer Res, 2015.

R. Bueno, E. W. Stawiski, L. D. Goldstein, S. Durinck, D. Rienzo et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-423, 2016.

A. Tallet, J. C. Nault, A. Renier, I. Hysi, F. Galateau-salle et al., Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-52, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478602

A. De-reynies, M. C. Jaurand, A. Renier, G. Couchy, I. Hysi et al., Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478599

U. Ehmer and J. Sage, Control of proliferation and cancer growth by the Hippo signaling pathway, Mol Cancer Res, 2015.

T. Yokoyama, H. Osada, H. Murakami, Y. Tatematsu, T. Taniguchi et al., YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation, Carcinogenesis, vol.29, pp.2139-2185, 2008.

T. Mizuno, H. Murakami, M. Fujii, F. Ishiguro, I. Tanaka et al., YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cyclepromoting genes, Oncogene, vol.31, pp.5117-5139, 2012.

E. Felley-bosco and R. Stahel, Hippo/YAP pathway for targeted therapy, Transl Lung Cancer Res, vol.3, pp.75-83, 2014.

H. Murakami, T. Mizuno, T. Taniguchi, M. Fujii, F. Ishiguro et al., LATS2 is a tumor suppressor gene of malignant mesothelioma, Cancer Res, vol.71, pp.873-83, 2011.

M. Bott, M. Brevet, B. S. Taylor, S. Shimizu, T. Ito et al., The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011.

D. Jean, E. Thomas, M. E. Renier, A. De-reynies, A. Lecomte et al., Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

P. Andujar, J. C. Pairon, A. Renier, A. Descatha, I. Hysi et al., Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478590

S. Rondeau, S. Vacher, D. Koning, L. Briaux, A. Schnitzler et al., ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels, Br J Cancer, vol.112, pp.1059-66, 2015.

S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He et al., NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PLoS One, vol.7, p.38686, 2012.

M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law et al., limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, vol.43, p.47, 2015.

M. C. Jaurand and D. Jean, Malignant Pleural Mesothelioma: Present Status and Future Directions: Bentham eBooks, pp.169-92, 2016.

A. Miyanaga, M. Masuda, K. Tsuta, K. Kawasaki, Y. Nakamura et al., Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing, J Thorac Oncol, vol.10, pp.844-51, 2015.

Q. Cui, A network of cancer genes with co-occurring and anti-co-occurring mutations, PLoS One, vol.5, 2010.

C. Thurneysen, I. Opitz, S. Kurtz, W. Weder, R. A. Stahel et al., Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, vol.64, pp.140-147, 2009.

J. Fleury-feith, C. Lecomte, A. Renier, M. Matrat, L. Kheuang et al., Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours, Oncogene, vol.22, pp.3799-805, 2003.
URL : https://hal.archives-ouvertes.fr/hal-01928405

J. Jongsma, E. Van-montfort, M. Vooijs, J. Zevenhoven, P. Krimpenfort et al., A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-71, 2008.

P. I. Poulikakos, G. H. Xiao, R. Gallagher, S. Jablonski, S. C. Jhanwar et al., Reexpression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK, Oncogene, vol.25, pp.5960-5968, 2006.

G. H. Xiao, R. Gallagher, J. Shetler, K. Skele, D. A. Altomare et al., The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression, Mol Cell Biol, vol.25, pp.2384-94, 2005.

H. J. Cha, J. Kim, S. M. Hong, S. J. Hong, J. H. Park et al., Overexpression of renal tumor antigen is associated with tumor invasion and poor prognosis of hepatocellular carcinoma, Ann Surg Oncol, vol.19, issue.3, pp.404-415, 2012.

E. Neumann, A. Engelsberg, J. Decker, S. Storkel, E. Jaeger et al., Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?, Cancer Res, vol.58, pp.4090-4095, 1998.

L. Sigalotti, S. Coral, M. Altomonte, L. Natali, G. Gaudino et al., Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications, Br J Cancer, vol.86, pp.979-82, 2002.

B. Zhao, X. Ye, J. Yu, L. Li, W. Li et al., TEAD mediates YAP-dependent gene induction and growth control, Genes Dev, vol.22, pp.1962-71, 2008.

C. Stein, A. F. Bardet, G. Roma, S. Bergling, I. Clay et al., YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers, PLoS Genet, vol.11, p.1005465, 2015.

Y. Liu-chittenden, B. Huang, J. S. Shim, Q. Chen, S. J. Lee et al., Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes Dev, vol.26, pp.1300-1305, 2012.

I. Tanaka, H. Osada, M. Fujii, A. Fukatsu, T. Hida et al., LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade, Oncogene, vol.34, pp.73-83, 2015.

M. A. Lopez-lago, T. Okada, M. M. Murillo, N. Socci, and F. G. Giancotti, Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling, Mol Cell Biol, vol.29, pp.4235-4284, 2009.

J. H. Mao, I. J. Kim, D. Wu, J. Climent, H. C. Kang et al., FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression, Science, vol.321, pp.1499-502, 2008.

Y. Hu, L. R. Carraro-lacroix, A. Wang, C. Owen, E. Bajenova et al., Lysosomal pH Plays a Key Role in Regulation of mTOR Activity in Osteoclasts, J Cell Biochem, vol.117, pp.413-438, 2016.

S. H. Ou, J. Moon, L. L. Garland, P. C. Mack, J. R. Testa et al., SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM), J Thorac Oncol, vol.10, pp.387-91, 2015.

A. Carracedo, L. Ma, J. Teruya-feldstein, F. Rojo, L. Salmena et al., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J Clin Invest, vol.118, pp.3065-74, 2008.

D. Barbone, T. M. Yang, J. R. Morgan, G. Gaudino, and V. C. Broaddus, Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids, J Biol Chem, vol.283, pp.13021-13051, 2008.

S. Zhou, L. Liu, H. Li, G. Eilers, Y. Kuang et al., Multipoint targeting of the PI3K/mTOR pathway in mesothelioma, Br J Cancer, vol.110, pp.2479-88, 2014.

N. Echeverry, G. Ziltener, D. Barbone, W. Weder, R. A. Stahel et al., Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors, Cell Death Dis, vol.6, p.1757, 2015.

H. Cheng, S. Bagrodia, S. Bailey, M. Edwards, J. Hoffman et al., Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design, Med Chem Commun, vol.1, pp.139-183, 2010.

F. Z. Wang, J. Peng, N. N. Yang, Y. Chuang, Y. L. Zhao et al., PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells, Toxicol Lett, vol.220, pp.150-156, 2013.

C. D. Britten, A. A. Adjei, R. Millham, B. E. Houk, G. Borzillo et al., Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer, Invest New Drugs, vol.32, pp.510-517, 2014.

D. Campo, J. M. Birrer, M. Davis, C. Fujiwara, K. Gollerkeri et al., A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer, Gynecol Oncol, 2016.